• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Schrodinger Inc.

    3/5/26 3:05:19 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001797672
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Schrodinger, Inc.
    SEC File Number
    001-39206
    Address of Issuer
    1540 BROADWAY
    24TH FLOOR
    NEW YORK
    NEW YORK
    10036
    Phone
    503-299-1150
    Name of Person for Whose Account the Securities are To Be Sold
    Akinsanya Karen
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    136617625.096466090803/05/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/04/2026Restricted Stock VestingIssuerCheckbox not checked136603/04/2026Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Karen O. Akinsanya-Akiwumi
    1540 Broadway
    24th Floor
    New York � NY � 10036
    Common03/02/2026220626454.36

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    03/05/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Karen O. Akinsanya-Akiwumi

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SDGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    12/15/2025$24.00Neutral → Buy
    BofA Securities
    9/30/2025$19.00Neutral
    Goldman
    8/15/2025$20.00Buy → Neutral
    Citigroup
    8/14/2025$25.00Overweight
    Barclays
    7/3/2025$28.00Equal-Weight
    Morgan Stanley
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    More analyst ratings

    $SDGR
    SEC Filings

    View All

    SEC Form 144 filed by Schrodinger Inc.

    144 - Schrodinger, Inc. (0001490978) (Subject)

    3/5/26 3:05:19 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Schrodinger Inc.

    10-K - Schrodinger, Inc. (0001490978) (Filer)

    2/25/26 4:11:39 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    2/25/26 4:09:01 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Schrodinger upgraded by BofA Securities with a new price target

    BofA Securities upgraded Schrodinger from Neutral to Buy and set a new price target of $24.00

    12/15/25 9:09:21 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Schrodinger with a new price target

    Goldman initiated coverage of Schrodinger with a rating of Neutral and set a new price target of $19.00

    9/30/25 8:57:53 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger downgraded by Citigroup with a new price target

    Citigroup downgraded Schrodinger from Buy to Neutral and set a new price target of $20.00

    8/15/25 8:18:12 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

    2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028 Accelerating Transition to Ratable, Hosted Software Revenue Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives. "Schrödinger's performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "

    2/25/26 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger to Participate in Upcoming Investor Conferences

    Schrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in the following conferences in March: TD Cowen 46th Annual Health Care Conference: Fireside chat on Tuesday, March 3, 2026 at 9:50 a.m. E.T. Leerink Global Healthcare Conference 2026: Fireside chat on Tuesday, March 10, 2026 at 1:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 17, 2026 at 9:00 a.m. E.T. The live discussions can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the disc

    2/24/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Schrödinger, Inc. (NASDAQ:SDGR) today reported that on February 13, 2026, the company granted (i) non-statutory stock options to purchase 9,600 shares of the company's common stock to two newly hired employees and (ii) restricted stock units (RSUs) with respect to 18,250 shares of the company's common stock to eight newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule

    2/18/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Farid Ramy was granted 118,113 shares and sold $66,151 worth of shares (5,560 units at $11.90), increasing direct ownership by 51% to 334,485 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/3/26 4:34:25 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO & CPO Tran Yvonne was granted 30,918 shares, increasing direct ownership by 135% to 53,777 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/3/26 4:33:31 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO & CPO Tran Yvonne sold $10,705 worth of shares (776 units at $13.80), decreasing direct ownership by 3% to 22,859 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    2/12/26 4:23:18 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    View All

    Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w

    5/29/25 8:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

    3/10/25 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

    Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim

    8/18/22 7:01:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Schrodinger Inc.

    SC 13G - Schrodinger, Inc. (0001490978) (Subject)

    11/13/24 4:30:25 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    2/13/24 5:13:59 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    1/23/24 11:52:31 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Financials

    Live finance-specific insights

    View All

    Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

    2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028 Accelerating Transition to Ratable, Hosted Software Revenue Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives. "Schrödinger's performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "

    2/25/26 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

    Schrödinger, Inc. (NASDAQ:SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed b

    2/11/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Reports Third Quarter 2025 Financial Results

    Third Quarter Total Revenue of $54.3 Million, Software Revenue of $40.9 Million Updates 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrödinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industry's increasing demand for our leading computational platform," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "While we are encouraged by the continued high level of customer engagement as the macroeconomic pressures that have affected the industry stabilize, we have lowered our software revenue growth guidance by two percent to 8% to 13%. This updated

    11/5/25 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care